Foundation Medicine signs Five-Year Veterans Affairs contract to provide tumor molecular tests to veterans with cancer. FM will use FoundationOne CDx and liquid-based FoundationOne Liquid CDx test as well as tissue-based FoudationOne RNA assays,
The Johnson and Johnson Phase III MARIPOSA trial of the activity of Rybrevant and Lazcluze as anti-EGFR therapy for NSCLC demonstrated significant improvement of progression-free survival compared to Tagrisso. www.genomeweb.com/cancer/liqui...
Molecular Designs acquires Lambda Biotech PCR assay maker Molecular Designs said Wednesday that it has acquired Lamda Biotech, a provider of research products for molecular biology, functional genomics, proteomics, and gene therapy. www.genomeweb.com/pcr/molecula...
I wrote a piece on the Phare 2 data readouts of REC-994 for @recursionpharma $RXRX and where it leaves the company and the value of the stock. Read all about it at Rhymes with Haystack, albertvilella.substack.com
Biotech Software Tools update August 2024 open.substack.com/pub/albertvi...
News from Genedata and DNAnexus
Which biotech companies mentioned in albertvilella.substack.com are of your interest?
Biotech, Next Generation Sequencing, Single cell and Spatial Biology, Next Generation Proteomics, Synthetic Biology and related topics. Click to read Rhymes with Haystack, a Substack publication with ...
Exact Sciences $EXAS enters the MCED segment albertvilella.substack.com/p/exact-scie...
Enter light, exit night for Exact Sciences on MCED
Biotech stock markets Q2 2024 overview open.substack.com/pub/albertvi...
Where am I long and where am I short